Search

You searched for "BSoT"

24 results found

BAUS Annual Scientific Meeting 2023

19 June 2023 -21 June 2023
Day 1 Highlights by: Omer Abdalla, Urology ST6 - Wirral University Teaching Hospitals, Mersey BSoT Trainee's rep (@Omer_Uro1). BAUS 2023 began last night with a wonderful welcome reception at the Birmingham Library, where urologists from throughout the UK met again,...

BCG strain differences have an impact on clinical outcome in bladder cancer immunotherapy

1 March 2015 | | Urologic Oncology | Animal, BCG Connaught, BCG Tice, BCG vaccine, Flow cytometry, Immunotherapy, Intravesical drug administration, Models, Randomized controlled trial, Urinary bladder neoplasms
Bacillus Calmette-Guérin (BCG) has been part of the treatment algorithm for non-muscle invasive bladder cancer (NMIBC) for a number of years. In this single centre, prospective, randomised trial, two of the most commonly available strains, BCG Connaught and BCG Tice,...

The Urology Foundation – 2019 Report

11 December 2019
It has been another busy year for The Urology Foundation in our mission to end the suffering caused by urology disease. We’ve taken big strides in some of the most crucial areas of our work as we work to prevent, treat and cure all urology disease.

BAUS Annual Meeting 2022

13 June 2022 -15 June 2022
The first face-to-face BAUS in three years began with a welcome reception in the Library of Birmingham. There was a great buzz of conversation between colleagues and friends, who potentially hadn’t seen each other since before the start of the...

BAUS 2023 Annual Scientific Meeting

4 May 2023 |
BAUS June 2022 was certainly noteworthy for me personally, as Tim O’Brien passed on the baton of Presidency. It was also a very special meeting for everyone who participated. The event felt so refreshing after two years of COVID and...

An overview of changes to urology training

1 January 2017 |
Paediatric urology training A review of paediatric emergency services in the UK involving general surgery, urology and paediatric surgery was initiated due to the problems encountered by the lack of suitable experience outside large paediatric surgical units to deliver emergency...

The life of a urology trainee in Singapore

1 November 2014 |
Despite the political and cultural differences between the United Kingdom and Singapore, the quality and nature of the medical training systems remain uniquely similar. It will come as no surprise to those of you who have either worked in Singapore...

OCERT: a new multi-specialty project to standardise robotic surgical training

3 June 2020 | | Technological Developments, Urologic Oncology
Since its introduction by Dr William Osler in 1890 to the Board of Trustees at John Hopkins Hospital [1], the Halstedian ‘See one, do one, teach one’ has represented a guideline for surgeons worldwide, both for open and laparoscopic surgery,...

Burnout: is this just a pandemic phenomenon?

28 July 2022 |
The phrase ‘burnout’ is often heard, but what is it, and what are the early warning signs? Importantly, how can it be prevented or managed? Over the last few years, health professional wellbeing, mental health, and burnout have come to...

Surgical video – part 2: Tips on how to edit and create a finished surgical video for teaching or publication

1 November 2015 | | Technological Developments
A well-made and informative video can be one of the most valuable promotional tools for a department of urology. Having to resort to an external commercial source to produce a video can be prohibitively expensive. With the extensive computing power...

Neuromodulation for lower urinary tract dysfunction – an ICS update

1 July 2018 | | Functional Urology, Technological Developments
Non-invasive and invasive electro-stimulation techniques have been extensively studied in the treatment of lower urinary tract and bowel dysfunction, including overactive bladder syndrome (OAB), non-obstructive chronic urinary retention, faecal incontinence and chronic pelvic pain. Currently, the most common indication for...

Trials offering cytoreductive surgery for men with de novo synchronous metastatic prostate cancer

8 November 2021 | | Basic Science Research, Urologic Oncology
Life expectancy in men diagnosed with de novo synchronous metastatic hormone-sensitive prostate cancer (mHSPC) has risen to a median of 4.8 years with upfront systemic agents (such as docetaxel) in addition to standard androgen deprivation therapy (ADT) [1-3]. Within this...
  • 1
  • 2 (current)